A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) | MicrobiomeTrials
A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2021-06-09Est. Completion: 2024-05-24
Enrollment target: 466 participants
Locations
Ah0003 50428, Fresno, California, United States
Ah0003 50431, Fullerton, California, United States
Ah0003 50442, Irvine, California, United States
Ah0003 50458, Long Beach, California, United States
Ah0003 50450, Palo Alto, California, United States
Ah0003 50452, Pasadena, California, United States
Ah0003 50447, San Diego, California, United States
Ah0003 50434, Santa Ana, California, United States
Ah0003 50422, New Haven, Connecticut, United States
Ah0003 50467, New Haven, Connecticut, United States
Ah0003 50421, Stamford, Connecticut, United States
Ah0003 50465, Atlantis, Florida, United States
Ah0003 50449, Aventura, Florida, United States
Ah0003 50435, Boca Raton, Florida, United States
Ah0003 50430, Delray Beach, Florida, United States
Ah0003 50429, Fort Myers, Florida, United States
Ah0003 50436, Hialeah, Florida, United States
Ah0003 50426, Maitland, Florida, United States
Other microbiome trials you might be interested in